Humalog

Surging Trulicity takes sting out of Lilly's arthritis setback

Trulicity's strong form - coupled with forecast-topping 17% growth for Lilly's insulin blockbuster Humalog to $708m and a $94m contribution from new psoriasis drug Taltz (ixekizumab) - helped Lilly boost

FDA approves Lilly-backed Bluetooth insulin device

The FDA approved Companion's InPen system for use with Lilly's Humalog or Novo Nordisk's Novolog rapid acting insulins and also passed its InPen app for Apple iOS.

Lilly's psoriasis drug Taltz cleared in Europe

Humalog (insulin lispro) which saw sales decline 11% to $606m in the quarter.

Novo Nordisk becomes diabetes drug sales leader

Lilly's sales hit $4.68bn in 2014 and has come predominately from its insulin range, led by Humalog, which saw sales grow by 7% last year to reach $2.78bn.

Lilly signs $570m deal for next-gen Humalog

Adocia pressed on with the project independently however and - in trials reported in September - reported that BioChaperone lispro exhibited a significantly faster onset of action compared to Humalog. ... The Humalog U200 product has been held up in the

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]